SUBSCRIBE
SUBSCRIBE
News   Policy

Human Genome Sciences, Inc.'s (JOBS) Anthrax Drug Denied Approval

November 16, 2009 | 
1 min read

Bookmark and Share

Reuters -- Human Genome Sciences Inc said the U.S. health regulators denied to approve its experimental anthrax drug raxibacumab -- which is being developed for use in the treatment of inhalational anthrax.

Regulatory
MORE ON THIS TOPIC
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Indivior, SpringWorks, More
February 3, 2025
 · 
5 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Approvals
Axsome’s Migraine Medicine Clears FDA Bar
January 31, 2025
 · 
2 min read
 · 
Tristan Manalac